MX2011012140A - Ranolazina para el tratamiento de problemas del snc. - Google Patents

Ranolazina para el tratamiento de problemas del snc.

Info

Publication number
MX2011012140A
MX2011012140A MX2011012140A MX2011012140A MX2011012140A MX 2011012140 A MX2011012140 A MX 2011012140A MX 2011012140 A MX2011012140 A MX 2011012140A MX 2011012140 A MX2011012140 A MX 2011012140A MX 2011012140 A MX2011012140 A MX 2011012140A
Authority
MX
Mexico
Prior art keywords
ranolazine
cns disorders
treatment
migraine
epilepsy
Prior art date
Application number
MX2011012140A
Other languages
English (en)
Spanish (es)
Inventor
Luiz Belardinelli
Sridharan Rajamani
Alfred George
Kristopher Kahlig
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2011012140A publication Critical patent/MX2011012140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011012140A 2009-05-14 2010-05-13 Ranolazina para el tratamiento de problemas del snc. MX2011012140A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17817009P 2009-05-14 2009-05-14
US27939509P 2009-10-20 2009-10-20
PCT/US2010/034778 WO2010132696A1 (en) 2009-05-14 2010-05-13 Ranolazine for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
MX2011012140A true MX2011012140A (es) 2012-02-28

Family

ID=42262042

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012140A MX2011012140A (es) 2009-05-14 2010-05-13 Ranolazina para el tratamiento de problemas del snc.

Country Status (7)

Country Link
US (1) US20100292217A1 (https=)
EP (1) EP2429526A1 (https=)
JP (1) JP2012526848A (https=)
AU (1) AU2010248948A1 (https=)
CA (1) CA2761771A1 (https=)
MX (1) MX2011012140A (https=)
WO (1) WO2010132696A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
ES2402675T3 (es) * 2007-05-31 2013-05-07 Gilead Palo Alto, Inc. Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN113318111B (zh) * 2021-06-21 2026-02-03 浙江大学 Nav1.1激动剂在制备治疗自闭症的药物中的应用
AU2024357729A1 (en) * 2023-10-12 2026-04-09 Celex Oncology Innovations Limited Treatment of metastatic or invasive brain cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IE80710B1 (en) * 1989-06-23 1998-12-16 Syntex Inc Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
DE69429524T2 (de) * 1993-09-24 2002-08-08 The University Of British Columbia, Vancouver Aminocyclohexylester und ihre anwendung
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
WO2001060348A2 (en) * 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
CN103356996A (zh) * 2000-05-19 2013-10-23 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
EP1406898B1 (en) * 2001-07-19 2005-04-06 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
JP2008519770A (ja) * 2004-11-09 2008-06-12 シーブイ・セラピューティクス・インコーポレイテッド 心不全の処置における左室リモデリングを逆転させるための少なくとも１種のリモデリング物質と併用するラノラジンの使用
US20060177502A1 (en) * 2005-01-06 2006-08-10 Srikonda Sastry Sustained release pharmaceutical formulations
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
CA2678515A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
ES2402675T3 (es) * 2007-05-31 2013-05-07 Gilead Palo Alto, Inc. Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados
CA2713521A1 (en) * 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2337559A2 (en) * 2008-09-04 2011-06-29 Gilead Sciences, Inc. Method of treating atrial fibrillation
US20100130436A1 (en) * 2008-11-25 2010-05-27 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides

Also Published As

Publication number Publication date
WO2010132696A1 (en) 2010-11-18
CA2761771A1 (en) 2010-11-18
US20100292217A1 (en) 2010-11-18
JP2012526848A (ja) 2012-11-01
AU2010248948A1 (en) 2011-12-01
EP2429526A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
GB201103062D0 (en) Method
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2011012140A (es) Ranolazina para el tratamiento de problemas del snc.
IN2014DN09804A (https=)
MX364602B (es) Inhibidores selectivos de glicosidasa y usos de los mismos.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
EP2485727A4 (en) PYRROLOPYRAZOLE FOR THE TREATMENT OF CNS DISEASES
MX2013007767A (es) Producto de desulfuracion resistente a la aglomeracion.
IL229658A0 (en) Scylo-inositol for the treatment of behavioral and psychiatric disorders
ZA201501262B (en) 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
UA102515C2 (ru) Новая лекарственная форма
MX351631B (es) Composiciones y metodos para reducir la incidencia de trastornos digestivos equinos.
EP2616056A4 (en) TERPENOID ANALOGUES AND USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL SUFFERING
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
MX2010002032A (es) Uso de flibanserina para el tratamiento de sintomas vasomotores.
MX2009009361A (es) Nueva forma de dosificacion.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
WO2012174552A3 (en) Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
EP3449917A3 (en) Tapentadol for preventing chronification of pain
MY174008A (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain

Legal Events

Date Code Title Description
FG Grant or registration